Recombinant Articles
PharmAthene gets additional $78.4 million under existing SparVax anthrax vaccine contract with HHS
24 February 2010
New Ph III data shows Merck & Co's Gardasil was effective against anal disease caused by HPV 6,11,16, and 18
18 February 2010
Biogen and Biovitrum update hemophilia agreement; MorphoSys and Galapagos expand accord
18 February 2010
Licensing deals: Debiopharm/Novartis; Teva/Active Biotech; Qiagen on biomarker; Merck & Co/AnaptysBio; and Novavax/ROVI accord dropped
9 February 2010
Austria’s Apeiron sells rights to early-stage lung disease drug to GlaxoSmithKline for as much as $332 million
4 February 2010
European approval for Merck & Co’s Elonva and new indication for Roche’s Herceptin; Roche sets up Singapore research hub
28 January 2010
Novartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal
27 January 2010
Bayer says Ph II BAY79-4980 recombinant Factor VIII trial will not meet primary endpoint
25 January 2010
Ipsen and Inspiration partner to create world leading hemophilia franchise that could be worth $1 billion
21 January 2010
Japanese Pharma market seeing more foreign entrants
21 January 2010
Sharp rise in US FDA approvals of biopharmaceuticals in 2009, highest since 2005, says BII
18 January 2010
Biogen Idec’s Tysabri surpasses $1 billion in 2009 sales; fampridine filed in EU, Canada; development deal with Trillium
13 January 2010
Class action against Australia’s CSL widens with US university claimant; Medicines Australia appoints permanent CEO
11 January 2010
Pfizer makes another move into generics in deal with Strides Arcolab; enters into discovery accord with Ensemble
7 January 2010
Novartis to buy Corthera for $120 million, plus up to $500 million on success of ADHF drug relaxin
23 December 2009
Court blocks Roche’s sales of Mircera in USA until 2014, as Amgen prevails in EPO patent dispute
23 December 2009
Bayer returns most rights to Recothrom to ZymoGenetics
22 December 2009
Merck & Co pays $52 million for Pfenex vaccine technology
14 December 2009
Ischemic stroke continues to be a graveyard for drug development, says Decision Resources, but market will grow to $450 million in 2018
18 November 2009
UK’s NICE won’t fund GSK’s breast cancer drug Tyverb; USA’s CDC backs Cervarix and Merck & Co’s Gardasil for boys
22 October 2009
Global biosimilars market driven by patent expiries, cost curbs and emerging economies
25 September 2009
US Appeals Court backs Amgen against Roche’s peg-EPO product
16 September 2009
Ipsen reveals positive findings with rhGH and Increlex
16 September 2009
Highlights of research presented at ICAAC
15 September 2009
Two new antibodies found to cripple HIV, say IAVI and Theraclone/Monogram scientists
4 September 2009
Global biosimilars product market worth $19.4 billion by 2014
2 September 2009
ZLB changes name to CSL Plasma
19 May 2009
DSM's XD Tech boosts yields five-10-fold
18 May 2009
Emergent Bio submits anthrax vacc plan to FDA
15 May 2009
Sales up by 84% cut loss for ZymoGenetics
8 May 2009
Lundbeck launches ATryn in USA
7 May 2009
ZymoGenetics out-licenses non-core drugs
6 May 2009
Sales up 18% in 1st qtr for Novo Nordisk
5 May 2009
InVitria's Cellastim improves cell growth
30 April 2009
ZymoGenetics to cut workforce by 32%
30 April 2009
Merck KGaA's 1st-qtr profit tumbles 76.3% to 56.7M euros on lower liquid crystal sales
27 April 2009
Baxter posts 20% jump in 1st-qtr profit
20 April 2009
XTL cuts loss, despite bificadine failure
9 April 2009
Intercell's S. pneumoniae vacc enters Ph I testing
8 April 2009
Pharming's Rhucin MAA to be submitted in September
2 April 2009
Japan stock market week to March 30, 2009
31 March 2009
Plant-derived insulin passes first human study
30 March 2009
AM-Pharma gets 5M-euro govt loan
23 March 2009
Baxter presents data validating Gammagard
23 March 2009
GTC pursuing legal action against LEO
23 March 2009
EC OKs Wyeth ReFacto MA variation
16 March 2009
GTC Bio gains $1M ATryn milestone
16 March 2009
Akron merges with ApliChem
16 March 2009
USPTO upholds Genentech's Cabilly patent
2 March 2009
Hawaii Bio shows safety of West Nile vacc
2 March 2009
Ph II trial of TB-402 starts enrolling
2 March 2009
Cerenis gets 2.5M euros from French govt
16 February 2009
Enzon Pharma drops rhMBL program
16 February 2009
Symphogen closes 33M-euro financing
16 February 2009
Leptin sensitizers lead to weight loss in mice
26 January 2009
Richter-Helm signs deal to develop Athera's ACS drug
26 January 2009
Hawaii Biotech completes dosing in Ph I trial of West Nile vacc
26 January 2009
Highlights of first PDCO meeting of 2009
26 January 2009
Halozyme earns milestone from Roche
26 January 2009
FDA panel gives nod to GTC's antithrombin
19 January 2009
Sanofi and Novozymes sign antibiotic deal
12 January 2009
Recipharm takes over AZ Swedish bio facility
12 January 2009
PDCO meeting sees good news for J&J but a mix for GSK and AZ; Janssen pulls Invega app
12 January 2009
SemBioSys gets $2.5M from MannKind for plant-based insulin
12 January 2009
Savient's pegloticase BLA accepted for review by FDA
12 January 2009
Bayer sues Abbott for slice of Humira earnings
12 January 2009
GSK licenses PER.C6 to research a protein
12 January 2009
Ferring and Conaris enter deal to develop IBD drug
22 December 2008
Astellas Pharma licenses Millipore's UCOE
15 December 2008
Symphogen and Meiji advance Sym006 into preclinical testing
15 December 2008
US orphan status for Biovitrum/Biogen drug
1 December 2008
Biovitrum/Symphogen completes proof-of-principle study
24 November 2008
Lasting benefits of CEL-SCI's RA vaccine demonstrated
24 November 2008
Biovitrum and Wyeth extend ReFacto supply deal
17 November 2008
GTC's 3rd-qtr net loss narrows to $6.1M
17 November 2008
Cytheris' CYT107 enters Ph I/IIa trial
3 November 2008
Avantogen CEO joins Hawaii Biotech board
27 October 2008
Bayer licenses Sartorius' UVivatec
27 October 2008
Baxter sales up 15% in 3rd-qtr 2008
27 October 2008
PharmAthene gets $1.6M to continue Protexia development
20 October 2008
Bayer's Factor VIII drug gets FDA go-ahead
20 October 2008
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
